McCormick Frank
University of California San Francisco, Cancer Research Institute, CA 94115, USA.
Oncogene. 2005 Nov 21;24(52):7817-9. doi: 10.1038/sj.onc.1209064.
Viruses have been engineered to replicate selectively in cancer cells, based on a number of innovative principles. Several of these viruses have entered clinical trials and have proven relatively safe, and have shown evidence of efficacy. However, further research is required to enable these agents to function systemically. This might involve attempts to suppress immune responses to virus antigens, and re-targeting of viruses to favor tumor infection and increased potency. When these barriers are overcome, oncolytic viruses could enter the mainstream of clinical oncology.
基于一些创新原理，病毒已被设计成可在癌细胞中选择性复制。其中几种病毒已进入临床试验，且已证明相对安全，并显示出疗效证据。然而，需要进一步研究以使这些制剂能够在全身发挥作用。这可能涉及抑制对病毒抗原的免疫反应，以及重新靶向病毒以促进肿瘤感染并提高效力。当这些障碍被克服时，溶瘤病毒可能会进入临床肿瘤学的主流。
